A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
- 1 September 1999
- journal article
- clinical trial
- Published by Elsevier in Leukemia Research
- Vol. 23 (9) , 787-794
- https://doi.org/10.1016/s0145-2126(99)00087-9
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group studyBlood, 1996
- Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center studyAnnals of Hematology, 1996
- High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemiaAnnals of Hematology, 1995
- The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup StudyBritish Journal of Haematology, 1992
- High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adultsBlood, 1991
- High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.Journal of Clinical Oncology, 1985
- High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot studyBlood, 1985
- High-dose cytosine arabinoside therapy for refractory leukemiaBlood, 1983
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958